CD Formulation is a biologic drug formulation development solution company dedicated to providing integrated services from pre-formulation development to commercial production of proteins, peptides, nucleic acids and other drug formulations.
Biomacromolecules are a class of biomolecules that are produced using modern biotechnological methods and are used in the diagnosis, treatment or prevention of diseases. Currently, biotechnology drugs include proteins, peptides and cytokines produced by DNA recombinant technology, as well as various modifications of these products produced by protein engineering technology, and also include genes, antisense oligonucleotides and nucleases for gene therapy. Biomacromolecular drugs are developing rapidly, especially because their structural conservatism allows them to be well studied in animals to inform human studies, thus significantly shortening the development cycle.
CD Formulation has a one-stop R&D and production platform for biologics and is committed to providing integrated CDMO services including process development and analytical method development for nucleic acid drugs and protein drugs. The process development quality system ensures compliance, data integrity and traceability, and all trial deviations are rigorously studied and documented.
Current specific biopharmaceutical formulation solutions include the following:
CD Formulation has always been committed to providing the best quality to our customers and serving their interests. We are committed to helping our customers shorten the time from development to commercialization of biologic drugs and significantly reduce R&D costs and accelerate pharmaceutical translation for our customers.
CD Formulation's business covers all aspects of drug formulation, drug ingredients, drug development, drug testing, drug optimization, etc. We provide one-stop integrated services from pre-clinical to commercial manufacturing for our global pharmaceutical and biotech partners. In the future, we will continue to strengthen our technological barriers and enhance our R&D production and service capabilities to provide quality and diversified services to more new drug development start-ups, medium and large companies as well as pharmaceutical companies around the world.
If you have a requirement about our services, please contact us by phone or email, our colleagues will reply to you within three working days.